Table 2.
The demographic, laboratory, and clinical characteristics of COVID-19 and healthy subjects.
| Patients (N = 57) | Control (N = 40) | P value | |
|---|---|---|---|
| Sex | Male: 31 (54.4%) | Male: 21 (52.5%) | 0.85 |
| Female: 26 (45.6%) | Female: 19 (47.5%) | ||
| Smoking | 17 (29.82%) | 12 (30%) | 0.58 |
| Lymphocyte count (cell/μl) | 847 ± 142.44 | 3072 ± 814.57 | <0.001 |
| CRP | Negative: 2 (3.5%) | Negative: 40 (100%) | |
| Positive: 55 (96.5%) | |||
| 1+: 12 (21.05%) | |||
| 2+: 19 (33.34%) | |||
| 3+: 17 (29.83%) | |||
| 4+: 7 (12.28%) | |||
| ESR(mm/h) | 38.96 ± 24.36 | 7.7 ± 4.42 | <0.001 |
| Background disease | Diabetes: 7 (25.92%) | – | |
| Kidney disease (ESRD & CKD): 8 (29.62%) | |||
| Lung disease (COPD, asthma): 6 (22.22%) | |||
| Hypertension: 18 (31.58%) | |||
| Hypothyroidism: 1 (3.7%) | |||
| Colon cancer: 1 (3.7%) | |||
| IHD: 5 (18.51%) | |||
| CVA: 1 (3.7%) | |||
| RA: 1 (3.7%) | |||
| Window period (day) | 8.59 ± 7.24 | – | |
| Treatment | Anti-viral drugs: 19 (33.33%) | – | |
| Anti-inflammatory drugs (prednisolone): 6 (10.52%) | |||
| Antibiotics: 32 (56.15%) |
RT-PCR: real time polymerase chain reaction; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ESRD: end stage renal disease; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; IHD: ischemic heart disease; CVA: cerebrovascular accident; RA: rheumatoid arthritis.